[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pachyonychia-congenita\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pachyonychia-congenita":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100558021","phase-1-epidermal-growth-factor-receptor-inhibition-for-keratinopathies-100558021",false,"NCT06545695","Epidermal Growth Factor Receptor Inhibition for Keratinopathies","Inclusion Criteria:\n\nThe participant must be at least 18 years of age.\n\nThe participant must have a clinically and genetically confirmed diagnosis of a keratinopathy (Epidermolytic ichthyosis\u002FEI: KRT 1, 2, or 10 pathogenic variant; Epidermolytic palmoplantar keratoderma\u002FPPK: KRT 9; Pachyonychia congenita\u002FPC form of PPK: KRT 6a, 6b, 6c, 16, 17). A blood or saliva sample will be collected for genetic confirmation if the underlying genetic change has not been confirmed by a CLIA-approved laboratory.\n\nThe participant must have an investigator scored IGA at screening and baseline of at least 2 (moderate) at affected sites.\n\nThe participant must abstain from use of any investigational drug or biologic within 4 weeks or 5 half-lives if longer, oral retinoid or oral steroid for at least 4 weeks, and topical medications (prescription or over-the-counter) in the week before the 8-week observation period. Otherwise stable medications (at least a month before the observation period and continued) will be allowed.\n\nThe participant agrees to use standard of care with respect to bathing and exfoliation\u002Ffoot care, except in the week before the visits. Moisturizers\u002F emollients are allowed throughout the treatment period, but use must be consistent and withheld to the designated area of sampling on the arms (EI) or plantar foot (PC\u002FPPK) for 48 hours prior to visits when skin samples are taken.\n\nThe participant is willing to have blood collected for safety and biopsies for investigation of mechanism.\n\nParticipant is in good general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair the evaluation of the EI or PC\u002FPPK.\n\nParticipant is able and willing to follow all study instructions\n\nExclusion Criteria:\n\nThe participant has EI or PC\u002FPPK lesions on the assessment area that are infected or require therapy to treat the infection within 7 days of enrollment.\n\nThe participant has had major surgery during the past 4 weeks.\n\nParticipants have received an investigational drug or biologic within 4 weeks or 5 half-lives, whichever is longer, prior to starting treatment with and during treatment with erlotinib.\n\nParticipants must be off oral retinoid or oral steroid for at least 4 weeks before drug initiation.\n\nParticipants who require medications and OTC supplements that inhibit\u002F induce CYP3A4 activity to control concurrent medical conditions.\n\nParticipants with known hypersensitivity to any of the ingredients in the study medication formulation.\n\nParticipants previously treated for invasive cancer within the past 5 years unless the Investigator concludes history of cancer is not confounding to safety.\n\nParticipants who are pregnant, breastfeeding or planning to become pregnant during the study or within a month after the study ends.\n\nParticipants of childbearing potential who are unwilling or unable to comply with contraception measures.\n\nThe participant has any condition or situation which, in the Investigator's opinion, may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study.\n\nParticipants deemed by the investigator as unwilling or unable to remain compliant with all tests and procedures, adherence to the study drug administration regimen and other protocol-required activities.","ALL","18 Years",{"count":18,"type":19},44,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","Epidermal growth factor receptor (EGFR) signaling plays a key role in regulating epidermal cell proliferation, survival, and differentiation. Keratins form a scaffold with epidermal desmosomes that involves ErbB\u002F EGFR signaling and keratin deficiency makes keratinocytes more sensitive to EGFR activation. Erlotinib, an EGFR inhibitor, was approved 20 years ago for cancer treatment and is generally used at 150 mg daily in adults \\>50 kg. While gastrointestinal and cutaneous side effects commonly occur at doses of 150 mg, adverse events occur less often at lower doses. We first reported erlotinib as effective for Olmsted syndrome, a rare hereditary EDD with painful PPK that results from variants in TRPV3. Erlotinib is now the treatment of choice for children and adults with Olmsted syndrome. Erlotinib is thought to inhibit formation of a complex that includes TRPV3, EGFR, and its primary skin-based ligand, TGF-a, which in turn regulates keratinocyte proliferation and differentiation. High-throughput screening to identify compounds that stabilize keratin filaments have also pointed to the EGFR pathway for targeting. Reviews and recent case reports have suggested the benefit of erlotinib for PC,\n\nGiven these preliminary data, we hypothesize that EGFR activation is a characteristic feature of keratinopathies. Further, we expect that oral low-dose erlotinib will improve the scaling and skin thickening of the spectrum of keratinopathies and be tolerated by most patients. For those who experience pain, particularly from plantar involvement, we predict that erlotinib therapy will improve mobility and pain. Finally, we aim to find the mechanism by which erlotinib improves the phenotypes of the various keratinopathies to better understand these disorders and predict response. We will look specifically at the impact on differentiation vs. hyperproliferation and barrier function, as well as the immune modulatory effects of the erlotinib using a multi-omics approach.",[26,27,28],"Epidermolytic Ichthyosis","Palmoplantar Keratoderma","Pachyonychia Congenita","NOT_YET_RECRUITING","2026-01-30",{"date":32,"type":33},"2026-02-03","ACTUAL",{"date":35,"type":19},"2027-07-01",{"date":37,"type":19},"2031-06-30",{"name":39,"class":40},"Northwestern University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":41},"100488727","phase-3-a-study-evaluating-the-safety-and-pharmacokinetics-of-qtorin-rapamycin-39-anhydrous-gel-in-the-treatment-of-adults-with-pachyonychia-congenita-100488727","NCT05643872","A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita","A Multicenter Open-Label Treatment Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita","Key Inclusion Criteria:\n\n* Completed the PALV-05 (VAPAUS) study\n* Agree to contraceptive use\n\nKey Exclusion Criteria:\n\n* Females who are pregnant or breastfeeding\n* Concomitant use of sirolimus or any sirolimus-containing medications (systemic or topical)\n* Any significant concurrent condition that could adversely affect participation and\u002For the assessment of the safety and efficacy in the study\n* Prior or planned treatment, including surgery or other medically necessary intervention deemed by the investigator that could adversely affect participation and\u002For the assessment of the safety and efficacy in the study","16 Years",{"count":51,"type":19},45,[53],"PHASE3","PALV-08 is a multicenter, open-label treatment (OLT) study enrolling adults with Pachyonychia Congenita (PC) with genotyped keratin mutations KRT6A, KRT6B, KRT6C or KRT16 who were previously enrolled in the PALV-05 (VAPAUS) trial.\n\nThe purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or \"PTX-022\".",[28],"RECRUITING","2022-12-01",{"date":59,"type":33},"2022-12-09",{"date":61,"type":33},"2022-11-15",{"date":63,"type":19},"2023-11",{"name":65,"class":66},"Palvella Therapeutics, Inc.","INDUSTRY",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":78,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":41},"100233797","international-pachyonychia-congenita-research-registry-100233797","NCT02321423","International Pachyonychia Congenita Research Registry","IPCRR","Inclusion Criteria:\n\n* Clinical diagnosis of Pachyonychia Congenita or similar disorder\n\nExclusion Criteria:\n\n* N\u002FA",true,{"count":76,"type":19},2000,"1 Year","OBSERVATIONAL","International Pachyonychia Congenita Research Registry (IPCRR) is a patient registry for those suffering from Pachyonychia Congenita (PC). PC is an ultra-rare extremely painful skin disorder that causes painful blisters and callus on feet and sometimes hands, thickened nails, cysts and other features. The IPCRR consists of a questionnaire, patient photos, optional physician notes from telephone consultation to validate questionnaire and free genetic testing.",[28],[82,83,84,85,86,87,88,89,90,91,92],"Nail Dystrophy","Plantar Keratoderma","Palmar Keratoderma","Leukokeratosis","Cysts","Pain","KRT17","KRT16","KRT6A","KRT6B","KRT6C","2018-11-19",{"date":95,"type":33},"2018-11-21",{"date":97,"type":4},"2004-04",{"date":99,"type":19},"2030-12",{"name":101,"class":40},"Pachyonychia Congenita Project"]